Last reviewed · How we verify
NCT05799638: SEMI
Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT
trial testing Guideline-Directed Medication Treatment (GDMT) in Heart Failure With Reduced Ejection Fraction in 263 participants. Completed in 30 June 2024.
31 December 2023
Quick facts
| Lead sponsor | Chongqing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 263 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Guideline-Directed Medication Treatment (GDMT)
Conditions studied
- Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →
Sponsor
Chongqing Medical University
Who can join
18 and older, any sex, with Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SEMI trial is a single-center, real-world based prospective cohort study. The study enrolled acute heart failure patients admitting to the hospital and intended to accept heart failure therapy. The current guideline recommend ACEI/ARB/ARNI, β blocker, SGLT2i and MRA as the cornerstone medication of HFrEF therapy, but a part patients were intolerable to GDMT because of hypotension, hyperkalemia or renal insufficency. Vericiguat is a new medication therapy choice for the patients with heart failure with reduced ejection fraction (HFrEF), it may has less influence on blood pressure, it is unkonwn about the efficacy and safety of vericiguat in patients who were intolerable to GDMT.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.
Sahana U, Wehland M, Simonsen U, Schulz H, et al · · 2023 · cited 10× · PMID 37511587 · DOI 10.3390/ijms241411826 -
Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect.
Majid A, Hassan FO, Hoque MM, Gbadegoye JO, et al · · 2023 · cited 5× · PMID 37504569 · DOI 10.3390/jcdd10070313 -
Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.
Chen J, Liu J, Xiao R, Wang Y, et al · · 2026 · PMID 41848038 · DOI 10.1161/jaha.125.046168
Verify or expand the search:
- PubMed search for NCT05799638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Reduced Ejection Fraction
Currently open trials in the same condition.
- NCT07465653 — A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · Phase 1 · recruiting
- NCT07465679 — A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treat · active not recruiting
- NCT07275931 — Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study · NA · recruiting
- NCT06942221 — Digital Solutions in Heart Therapy (DIGNITY) · NA · recruiting
- NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting
Other Chongqing Medical University trials
Trials by the same sponsor.
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
- NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
- NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
- NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05799638 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
- Last refreshed: 1 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing